Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression
Identifieur interne : 009384 ( Main/Exploration ); précédent : 009383; suivant : 009385Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression
Auteurs : Robert Z. Orlowski [États-Unis, Israël, Pays-Bas, Espagne, République tchèque, Australie, Pologne, Canada, Russie, France] ; Arnon Nagler ; Pieter Sonneveld ; Joan Blade ; Roman Hajek ; Andrew Spencer ; Jesus San Miguel ; Tadeusz Robak ; Anna Dmoszynska ; Noemi Horvath ; Ivan Spicka ; Heather J. Sutherland ; Alexander N. Suvorov ; Sen H. Zhuang ; Trilok Parekh ; LIANG XIU ; ZHILONG YUAN ; Wayne Rackoff ; Jean-Luc HarousseauSource :
- Journal of clinical oncology [ 0732-183X ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Purpose This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma. Patients and Methods Six hundred forty-six patients were randomly assigned to receive either intravenous bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of an every 21-days cycle, or the same bortezomib regimen with PLD 30 mg/m2 on day 4. Results Median time to progression was increased from 6.5 months for bortezomib to 9.3 months with the PLD + bortezomib combination (P = .000004; hazard ratio, 1.82 [monotherapy v combination therapy]; 95% Cl, 1.41 to 2.35). The 15-month survival rate for PLD + bortezomib was 76% compared with 65% for bortezomib alone (P = .03). The complete plus partial response rate was 41% for bortezomib and 44% for PLD + bortezomib, a difference that was not statistically significant. Median duration of response was increased from 7.0 to 10.2 months (P = .0008) with PLD + bortezomib. Grade 3/4 adverse events were more frequent in the combination group (80% v 64%), with safety profiles consistent with the known toxicities of the two agents. An increased incidence in the combination group was seen of grade 3/4 neutropenia, thrombocytopenia, asthenia, fatigue, diarrhea, and hand-foot syndrome. Conclusion PLD with bortezomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma. The combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and Gl and dermatologic toxicities.
Affiliations:
- Australie, Canada, Espagne, France, Israël, Pays-Bas, Pologne, Russie, République tchèque, États-Unis
- Bohême centrale, Caroline du Nord, Catalogne, Hollande-Méridionale, Moravie, Pays de la Loire, Victoria (État)
- Barcelone, Brno, Chapel Hill (Caroline du Nord), Melbourne, Nantes, Prague, Rotterdam
- Université de Caroline du Nord à Chapel Hill
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 003969
- to stream PascalFrancis, to step Curation: 002719
- to stream PascalFrancis, to step Checkpoint: 003669
- to stream Main, to step Merge: 009D81
- to stream Main, to step Curation: 009384
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression</title><author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of North Carolina at Chapel Hill</s1><s2>Chapel Hill, NC</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Chaim Sheba Medical Center</s1><s2>Tel Hashomer</s2><s3>ISR</s3></inist:fA14><country>Israël</country><wicri:noRegion>Chaim Sheba Medical Center</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Erasmus MC</s1><s2>Rotterdam</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Hospital Clinic I Provincial</s1><s2>Barcelona</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Interni Hematoonkologická klinika Fakultní Brno</s1><s2>Brno</s2><s3>CZE</s3></inist:fA14><country>République tchèque</country><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>General Faculty Hospital</s1><s2>Prague</s2><s3>CZE</s3></inist:fA14><country>République tchèque</country><placeName><settlement type="city">Prague</settlement><region type="région" nuts="2">Bohême centrale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Alfred Hospital</s1><s2>Melbourne</s2><s3>AUS</s3></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Institute of Medicine and Veterinary Science</s1><s2>Adelaide</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Institute of Medicine and Veterinary Science</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Hospital Universitario de Salamanca, Centro de Investigación del Cáncer-IBMCC (CSIC-USAL)</s1><s3>ESP</s3></inist:fA14><country>Espagne</country><wicri:noRegion>Hospital Universitario de Salamanca, Centro de Investigación del Cáncer-IBMCC (CSIC-USAL)</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Medical University of Lodz</s1><s2>Lodz</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Medical University of Lodz</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Medical University of Lublin</s1><s2>Lublin</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Medical University of Lublin</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>University of British Columbia</s1><s2>Vancouver</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>University of British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>First Republican Clinical Hospital of Udmurtia</s1><s2>Izhevsk</s2><s3>RUS</s3></inist:fA14><country>Russie</country><wicri:noRegion>First Republican Clinical Hospital of Udmurtia</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Johnson & Johnson Pharmaceutical Research & Development LLC</s1><s2>Raritan, NJ</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Johnson & Johnson Pharmaceutical Research & Development LLC</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="15"><s1>University Hospital Hotel-Dieu</s1><s2>Nantes</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name></author><author><name sortKey="Sonneveld, Pieter" sort="Sonneveld, Pieter" uniqKey="Sonneveld P" first="Pieter" last="Sonneveld">Pieter Sonneveld</name></author><author><name sortKey="Blade, Joan" sort="Blade, Joan" uniqKey="Blade J" first="Joan" last="Blade">Joan Blade</name></author><author><name sortKey="Hajek, Roman" sort="Hajek, Roman" uniqKey="Hajek R" first="Roman" last="Hajek">Roman Hajek</name></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name></author><author><name sortKey="San Miguel, Jesus" sort="San Miguel, Jesus" uniqKey="San Miguel J" first="Jesus" last="San Miguel">Jesus San Miguel</name></author><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></author><author><name sortKey="Dmoszynska, Anna" sort="Dmoszynska, Anna" uniqKey="Dmoszynska A" first="Anna" last="Dmoszynska">Anna Dmoszynska</name></author><author><name sortKey="Horvath, Noemi" sort="Horvath, Noemi" uniqKey="Horvath N" first="Noemi" last="Horvath">Noemi Horvath</name></author><author><name sortKey="Spicka, Ivan" sort="Spicka, Ivan" uniqKey="Spicka I" first="Ivan" last="Spicka">Ivan Spicka</name></author><author><name sortKey="Sutherland, Heather J" sort="Sutherland, Heather J" uniqKey="Sutherland H" first="Heather J." last="Sutherland">Heather J. Sutherland</name></author><author><name sortKey="Suvorov, Alexander N" sort="Suvorov, Alexander N" uniqKey="Suvorov A" first="Alexander N." last="Suvorov">Alexander N. Suvorov</name></author><author><name sortKey="Zhuang, Sen H" sort="Zhuang, Sen H" uniqKey="Zhuang S" first="Sen H." last="Zhuang">Sen H. Zhuang</name></author><author><name sortKey="Parekh, Trilok" sort="Parekh, Trilok" uniqKey="Parekh T" first="Trilok" last="Parekh">Trilok Parekh</name></author><author><name sortKey="Liang Xiu" sort="Liang Xiu" uniqKey="Liang Xiu" last="Liang Xiu">LIANG XIU</name></author><author><name sortKey="Zhilong Yuan" sort="Zhilong Yuan" uniqKey="Zhilong Yuan" last="Zhilong Yuan">ZHILONG YUAN</name></author><author><name sortKey="Rackoff, Wayne" sort="Rackoff, Wayne" uniqKey="Rackoff W" first="Wayne" last="Rackoff">Wayne Rackoff</name></author><author><name sortKey="Harousseau, Jean Luc" sort="Harousseau, Jean Luc" uniqKey="Harousseau J" first="Jean-Luc" last="Harousseau">Jean-Luc Harousseau</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0442439</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0442439 INIST</idno><idno type="RBID">Pascal:07-0442439</idno><idno type="wicri:Area/PascalFrancis/Corpus">003969</idno><idno type="wicri:Area/PascalFrancis/Curation">002719</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003669</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003669</idno><idno type="wicri:doubleKey">0732-183X:2007:Orlowski R:randomized:phase:iii</idno><idno type="wicri:Area/Main/Merge">009D81</idno><idno type="wicri:Area/Main/Curation">009384</idno><idno type="wicri:Area/Main/Exploration">009384</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression</title><author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of North Carolina at Chapel Hill</s1><s2>Chapel Hill, NC</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Chaim Sheba Medical Center</s1><s2>Tel Hashomer</s2><s3>ISR</s3></inist:fA14><country>Israël</country><wicri:noRegion>Chaim Sheba Medical Center</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Erasmus MC</s1><s2>Rotterdam</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Hospital Clinic I Provincial</s1><s2>Barcelona</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Interni Hematoonkologická klinika Fakultní Brno</s1><s2>Brno</s2><s3>CZE</s3></inist:fA14><country>République tchèque</country><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>General Faculty Hospital</s1><s2>Prague</s2><s3>CZE</s3></inist:fA14><country>République tchèque</country><placeName><settlement type="city">Prague</settlement><region type="région" nuts="2">Bohême centrale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Alfred Hospital</s1><s2>Melbourne</s2><s3>AUS</s3></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Institute of Medicine and Veterinary Science</s1><s2>Adelaide</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Institute of Medicine and Veterinary Science</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Hospital Universitario de Salamanca, Centro de Investigación del Cáncer-IBMCC (CSIC-USAL)</s1><s3>ESP</s3></inist:fA14><country>Espagne</country><wicri:noRegion>Hospital Universitario de Salamanca, Centro de Investigación del Cáncer-IBMCC (CSIC-USAL)</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Medical University of Lodz</s1><s2>Lodz</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Medical University of Lodz</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Medical University of Lublin</s1><s2>Lublin</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Medical University of Lublin</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>University of British Columbia</s1><s2>Vancouver</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>University of British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>First Republican Clinical Hospital of Udmurtia</s1><s2>Izhevsk</s2><s3>RUS</s3></inist:fA14><country>Russie</country><wicri:noRegion>First Republican Clinical Hospital of Udmurtia</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Johnson & Johnson Pharmaceutical Research & Development LLC</s1><s2>Raritan, NJ</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Johnson & Johnson Pharmaceutical Research & Development LLC</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="15"><s1>University Hospital Hotel-Dieu</s1><s2>Nantes</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name></author><author><name sortKey="Sonneveld, Pieter" sort="Sonneveld, Pieter" uniqKey="Sonneveld P" first="Pieter" last="Sonneveld">Pieter Sonneveld</name></author><author><name sortKey="Blade, Joan" sort="Blade, Joan" uniqKey="Blade J" first="Joan" last="Blade">Joan Blade</name></author><author><name sortKey="Hajek, Roman" sort="Hajek, Roman" uniqKey="Hajek R" first="Roman" last="Hajek">Roman Hajek</name></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name></author><author><name sortKey="San Miguel, Jesus" sort="San Miguel, Jesus" uniqKey="San Miguel J" first="Jesus" last="San Miguel">Jesus San Miguel</name></author><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></author><author><name sortKey="Dmoszynska, Anna" sort="Dmoszynska, Anna" uniqKey="Dmoszynska A" first="Anna" last="Dmoszynska">Anna Dmoszynska</name></author><author><name sortKey="Horvath, Noemi" sort="Horvath, Noemi" uniqKey="Horvath N" first="Noemi" last="Horvath">Noemi Horvath</name></author><author><name sortKey="Spicka, Ivan" sort="Spicka, Ivan" uniqKey="Spicka I" first="Ivan" last="Spicka">Ivan Spicka</name></author><author><name sortKey="Sutherland, Heather J" sort="Sutherland, Heather J" uniqKey="Sutherland H" first="Heather J." last="Sutherland">Heather J. Sutherland</name></author><author><name sortKey="Suvorov, Alexander N" sort="Suvorov, Alexander N" uniqKey="Suvorov A" first="Alexander N." last="Suvorov">Alexander N. Suvorov</name></author><author><name sortKey="Zhuang, Sen H" sort="Zhuang, Sen H" uniqKey="Zhuang S" first="Sen H." last="Zhuang">Sen H. Zhuang</name></author><author><name sortKey="Parekh, Trilok" sort="Parekh, Trilok" uniqKey="Parekh T" first="Trilok" last="Parekh">Trilok Parekh</name></author><author><name sortKey="Liang Xiu" sort="Liang Xiu" uniqKey="Liang Xiu" last="Liang Xiu">LIANG XIU</name></author><author><name sortKey="Zhilong Yuan" sort="Zhilong Yuan" uniqKey="Zhilong Yuan" last="Zhilong Yuan">ZHILONG YUAN</name></author><author><name sortKey="Rackoff, Wayne" sort="Rackoff, Wayne" uniqKey="Rackoff W" first="Wayne" last="Rackoff">Wayne Rackoff</name></author><author><name sortKey="Harousseau, Jean Luc" sort="Harousseau, Jean Luc" uniqKey="Harousseau J" first="Jean-Luc" last="Harousseau">Jean-Luc Harousseau</name></author></analytic><series><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Bortezomib</term><term>Cancerology</term><term>Combined treatment</term><term>Comparative study</term><term>Doxorubicin</term><term>Liposome</term><term>Myeloma</term><term>Pegylated form</term><term>Phase III trial</term><term>Randomization</term><term>Relapse</term><term>Treatment resistance</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique phase III</term><term>Randomisation</term><term>Forme pégylée</term><term>Doxorubicine</term><term>Liposome</term><term>Etude comparative</term><term>Traitement associé</term><term>Récidive</term><term>Résistance traitement</term><term>Bortézomib</term><term>Cancérologie</term><term>Myélome</term><term>Anticancéreux</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma. Patients and Methods Six hundred forty-six patients were randomly assigned to receive either intravenous bortezomib 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of an every 21-days cycle, or the same bortezomib regimen with PLD 30 mg/m<sup>2</sup> on day 4. Results Median time to progression was increased from 6.5 months for bortezomib to 9.3 months with the PLD + bortezomib combination (P = .000004; hazard ratio, 1.82 [monotherapy v combination therapy]; 95% Cl, 1.41 to 2.35). The 15-month survival rate for PLD + bortezomib was 76% compared with 65% for bortezomib alone (P = .03). The complete plus partial response rate was 41% for bortezomib and 44% for PLD + bortezomib, a difference that was not statistically significant. Median duration of response was increased from 7.0 to 10.2 months (P = .0008) with PLD + bortezomib. Grade 3/4 adverse events were more frequent in the combination group (80% v 64%), with safety profiles consistent with the known toxicities of the two agents. An increased incidence in the combination group was seen of grade 3/4 neutropenia, thrombocytopenia, asthenia, fatigue, diarrhea, and hand-foot syndrome. Conclusion PLD with bortezomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma. The combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and Gl and dermatologic toxicities.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Israël</li><li>Pays-Bas</li><li>Pologne</li><li>Russie</li><li>République tchèque</li><li>États-Unis</li></country><region><li>Bohême centrale</li><li>Caroline du Nord</li><li>Catalogne</li><li>Hollande-Méridionale</li><li>Moravie</li><li>Pays de la Loire</li><li>Victoria (État)</li></region><settlement><li>Barcelone</li><li>Brno</li><li>Chapel Hill (Caroline du Nord)</li><li>Melbourne</li><li>Nantes</li><li>Prague</li><li>Rotterdam</li></settlement><orgName><li>Université de Caroline du Nord à Chapel Hill</li></orgName></list><tree><noCountry><name sortKey="Blade, Joan" sort="Blade, Joan" uniqKey="Blade J" first="Joan" last="Blade">Joan Blade</name><name sortKey="Dmoszynska, Anna" sort="Dmoszynska, Anna" uniqKey="Dmoszynska A" first="Anna" last="Dmoszynska">Anna Dmoszynska</name><name sortKey="Hajek, Roman" sort="Hajek, Roman" uniqKey="Hajek R" first="Roman" last="Hajek">Roman Hajek</name><name sortKey="Harousseau, Jean Luc" sort="Harousseau, Jean Luc" uniqKey="Harousseau J" first="Jean-Luc" last="Harousseau">Jean-Luc Harousseau</name><name sortKey="Horvath, Noemi" sort="Horvath, Noemi" uniqKey="Horvath N" first="Noemi" last="Horvath">Noemi Horvath</name><name sortKey="Liang Xiu" sort="Liang Xiu" uniqKey="Liang Xiu" last="Liang Xiu">LIANG XIU</name><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name><name sortKey="Parekh, Trilok" sort="Parekh, Trilok" uniqKey="Parekh T" first="Trilok" last="Parekh">Trilok Parekh</name><name sortKey="Rackoff, Wayne" sort="Rackoff, Wayne" uniqKey="Rackoff W" first="Wayne" last="Rackoff">Wayne Rackoff</name><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><name sortKey="San Miguel, Jesus" sort="San Miguel, Jesus" uniqKey="San Miguel J" first="Jesus" last="San Miguel">Jesus San Miguel</name><name sortKey="Sonneveld, Pieter" sort="Sonneveld, Pieter" uniqKey="Sonneveld P" first="Pieter" last="Sonneveld">Pieter Sonneveld</name><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><name sortKey="Spicka, Ivan" sort="Spicka, Ivan" uniqKey="Spicka I" first="Ivan" last="Spicka">Ivan Spicka</name><name sortKey="Sutherland, Heather J" sort="Sutherland, Heather J" uniqKey="Sutherland H" first="Heather J." last="Sutherland">Heather J. Sutherland</name><name sortKey="Suvorov, Alexander N" sort="Suvorov, Alexander N" uniqKey="Suvorov A" first="Alexander N." last="Suvorov">Alexander N. Suvorov</name><name sortKey="Zhilong Yuan" sort="Zhilong Yuan" uniqKey="Zhilong Yuan" last="Zhilong Yuan">ZHILONG YUAN</name><name sortKey="Zhuang, Sen H" sort="Zhuang, Sen H" uniqKey="Zhuang S" first="Sen H." last="Zhuang">Sen H. Zhuang</name></noCountry><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></region><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></country><country name="Israël"><noRegion><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></region></country><country name="Espagne"><region name="Catalogne"><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></region><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></country><country name="République tchèque"><region name="Moravie"><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></region><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></region><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></country><country name="Pologne"><noRegion><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></noRegion><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></country><country name="Canada"><noRegion><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></noRegion></country><country name="Russie"><noRegion><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></noRegion></country><country name="France"><region name="Pays de la Loire"><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009384 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009384 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:07-0442439
|texte= Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression
}}
| This area was generated with Dilib version V0.6.33. |  |